A Study of AT-101 in Combination With Docetaxel in Squamous Cell Carcinoma Of The Head and Neck
Status:
Terminated
Trial end date:
2015-09-01
Target enrollment:
Participant gender:
Summary
This study will examine the effects of an investigational drug called AT-101 in combination
with an FDA approved cancer drug called Docetaxel. It is hoped that AT-101 will help the
Docetaxel to have a better effect in slowing or stopping cancer cell growth. This study will
help the researchers learn what effects, if any, the combination of AT-101 and Docetaxel has
on your cancer. For instance, will the combination cause your tumor(s) to shrink or stop
growing? The researchers will also learn about the safety of the combination of AT-101 and
Docetaxel. For instance, are there any side effects? If so, what kind of side effects does
the combination cause? How severe are the side effects, and how often do they occur?
Phase:
Phase 2
Details
Lead Sponsor:
University of Michigan Cancer Center University of Michigan Rogel Cancer Center